Fate Therapeutics (FATE) EBIT Margin (2012 - 2026)
Fate Therapeutics (FATE) reported EBIT Margin of 2540.42% for Q1 2026, down 635.0% on a YoY basis from 474.84% in Q1 2025, and little changed quarter-over-quarter from 2536.23% in Q4 2025.
Fate Therapeutics (FATE) EBIT Margin (2012 - 2026) Analysis & Trends
Fate Therapeutics has reported EBIT Margin for 14 years, with the latest figure at 2540.42% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 635.0% year-over-year to 2540.42%; the trailing twelve-month figure through Mar 2026 stood at 2207.47% (down 70400.0% YoY), and the FY2025 full-year result was 2222.45%, down 67982.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 2540.42%, roughly flat from 2536.23% in the prior quarter.
- The five-year high for EBIT Margin was 48.48% in Q1 2023, with the low at 6705.79% in Q2 2023.
- Historically, EBIT Margin has averaged 1983.62% across 5 years, with a median of 1995.12% in 2025.
- Annual changes were most pronounced in 2023 — EBIT Margin plunged 625774 bps — and 2024, when it soared 604006 bps.
- Fate Therapeutics' EBIT Margin stood at 145.23% in 2022, then slumped by 1875 bps to 2868.44% in 2023, then fell by 16 bps to 3319.78% in 2024, then grew by 24 bps to 2536.23% in 2025, then fell by 0 bps to 2540.42% in 2026.
- The last three EBIT Margin figures came in at 2540.42% (Q1 2026), 2536.23% (Q4 2025), and 1995.12% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Fate Therapeutics | 250.86 Mn | 250.86 Mn | - | -2,540.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,540.42% |
| Dec 31, 2025 | -2,536.23% |
| Sep 30, 2025 | -1,995.12% |
| Jun 30, 2025 | -1,938.54% |
| Mar 31, 2025 | -2,534.07% |
| Dec 31, 2024 | -3,319.78% |
| Sep 30, 2024 | -1,703.87% |
| Jun 30, 2024 | -665.73% |
| Mar 31, 2024 | -2,652.88% |
| Dec 31, 2023 | -2,868.44% |
| Sep 30, 2023 | -2,637.81% |
| Jun 30, 2023 | -6,705.79% |
| Mar 31, 2023 | -48.48% |
| Dec 31, 2022 | -145.23% |
| Sep 30, 2022 | -576.67% |
| Jun 30, 2022 | -448.05% |
| Mar 31, 2022 | -404.40% |
| Dec 31, 2021 | -406.48% |
| Sep 30, 2021 | -383.99% |
| Jun 30, 2021 | -348.78% |